Inotrem
PrivateLast Round
Grant
Nov 6, 2023
Total Funding Raised
$259.66M
Company Overview
Inotrem is a biotechnology company that develops innovative immunotherapies targeting the TREM-1 pathway to treat acute and chronic inflammatory syndromes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inotrem Comparables
Compare Inotrem with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adrenomed AG | 86% | |
| Matisse Pharmaceuticals | 85% | |
| 4TEEN4 Pharmaceuticals GmbH | 81% |
Inotrem Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 6, 2023 | ||||
| Grant | Dec 1, 2022 | ||||
| Grant | Nov 2, 2021 | ||||
| Grant | Jul 12, 2021 | ||||
| Grant | Jul 1, 2020 | ||||
Series B | Feb 10, 2020 |
Key People
Founding team and executive leadership
Inotrem Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kreos Capital | Debt |
| BioMedPartners | Series A, Series B |
| Andera Partners | Series B, Series A |
| Kreos Capital | Debt |
| Inserm Transfert | Series A |
| Morningside Ventures | Series B |
| Edmond de Rothschild | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 6, 2023
Received grant from the Crohn's & Colitis Foundation.
- Jul 12, 2021
$53.37M grant received from Bpifrance.
Recent news
Latest coverage and updates
- receives_financingSep 15, 2026
In 2014, Inotrem SA receives $20.9M in Series A financing co-led by Edmond de Rothschild Investment Partners and Sofinnova Partners in France.
- receives_financingSep 15, 2026
Inotrem SA receives $67.2M in equity and debt in France in 2020 as it tests nangibotide in COVID-19 patients.
- sells_assets_toSep 15, 2026
In Summer '26, Genfit completes its acquisition of nangibotide from Inotrem SA and plans to start a Phase 2a trial in acute-on-chronic liver failure in Q4 '26.
Inotrem Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Inotrem's valuation, stock price, and market status.
Is Inotrem a public or private company?
Inotrem is a private company.
What is the current stock price of Inotrem?
Inotrem is a private company, so its shares have no public market price. Caplight tracks Inotrem's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Inotrem worth (valuation)?
Valuation information for Inotrem is not publicly available.
Can I buy Inotrem stock?
Inotrem shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Inotrem's last funding round?
Inotrem's most recent funding round was Grant on November 6, 2023.
Who are the main investors in Inotrem?
Key investors in Inotrem include Andera Partners, Morningside Ventures, Edmond de Rothschild, Fountain Healthcare Partners, Sofinnova Partners.
Will Inotrem IPO soon?
No public IPO plans have been announced for Inotrem.
How can I track Inotrem secondary market activity?
Caplight tracks bids, offers, and trades in Inotrem's shares on secondary markets.